These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33559375)

  • 1. The cerebellum could serve as a potential imaging biomarker of dementia conversion in patients with amyloid-negative amnestic mild cognitive impairment.
    Kim HJ; Cheong EN; Jo S; Lee S; Shim WH; Kwon M; Kim JS; Kim BJ; Lee JH
    Eur J Neurol; 2021 May; 28(5):1520-1527. PubMed ID: 33559375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment.
    Kim HJ; Oh JS; Lim JS; Lee S; Jo S; Chung EN; Shim WH; Oh M; Kim JS; Roh JH; Lee JH;
    Alzheimers Res Ther; 2022 Jul; 14(1):93. PubMed ID: 35821150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidating the Risk Factors for Progression from Amyloid-Negative Amnestic Mild Cognitive Impairment to Dementia.
    Kim HJ; Lee JH; Cheong EN; Chung SE; Jo S; Shim WH; Hong YJ
    Curr Alzheimer Res; 2020; 17(10):893-903. PubMed ID: 33256581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Impairment in the Ventral Visual Pathway Can Predict Conversion to Dementia in Patients With Amyloid-negative Amnestic Mild Cognitive Impairment.
    Kim HJ; Cheong EN; Jo S; Lee S; Shim WH; Kang DW; Kwon M; Kim JS; Lee JH
    Alzheimer Dis Assoc Disord; 2021 Oct-Dec 01; 35(4):298-305. PubMed ID: 34132669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance image-based brain age as a discriminator of dementia conversion in patients with amyloid-negative amnestic mild cognitive impairment.
    Kim HW; Kim HJ; Lee H; Yang H; Rieu Z; Lee JH
    Sci Rep; 2023 Dec; 13(1):22467. PubMed ID: 38105274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study.
    Goukasian N; Hwang KS; Romero T; Grotts J; Do TM; Groh JR; Bateman DR; Apostolova LG
    BMJ Open; 2019 Dec; 9(12):e031947. PubMed ID: 31857304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment.
    Grimmer T; Wutz C; Drzezga A; Förster S; Förstl H; Ortner M; Perneczky R; Kurz A
    Curr Alzheimer Res; 2013 Jan; 10(1):82-5. PubMed ID: 23036071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-β Positron Emission Tomography.
    Beyer L; Brendel M; Scheiwein F; Sauerbeck J; Hosakawa C; Alberts I; Shi K; Bartenstein P; Ishii K; Seibyl J; Cumming P; Rominger A;
    J Alzheimers Dis; 2020; 74(1):101-112. PubMed ID: 31985461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Alzheimer's Dementia in Patients with Amnestic Mild Cognitive Impairment in Clinical Routine: Incremental Value of Biomarkers of Neurodegeneration and Brain Amyloidosis Added Stepwise to Cognitive Status.
    Lange C; Suppa P; Pietrzyk U; Makowski MR; Spies L; Peters O; Buchert R;
    J Alzheimers Dis; 2018; 61(1):373-388. PubMed ID: 29154285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cerebellum shrinks faster than normal ageing in Alzheimer's disease but not in mild cognitive impairment.
    Tabatabaei-Jafari H; Walsh E; Shaw ME; Cherbuin N;
    Hum Brain Mapp; 2017 Jun; 38(6):3141-3150. PubMed ID: 28321950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid deposition and CBF patterns predict conversion of mild cognitive impairment to dementia.
    Kikukawa T; Abe T; Ataka S; Saito H; Hasegawa I; Mino T; Takeuchi J; Kawabe J; Wada Y; Watanabe Y; Itoh Y
    Neurol Sci; 2018 Sep; 39(9):1597-1602. PubMed ID: 29936556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.
    Edison P; Carter SF; Rinne JO; Gelosa G; Herholz K; Nordberg A; Brooks DJ; Hinz R
    Neuroimage; 2013 Apr; 70():423-33. PubMed ID: 23261639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration.
    Santana I; Baldeiras I; Santiago B; Duro D; Freitas S; Pereira MT; Almeida MR; Oliveira CR
    J Alzheimers Dis; 2018; 64(s1):S647-S657. PubMed ID: 29562515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment.
    Ten Kate M; Barkhof F; Visser PJ; Teunissen CE; Scheltens P; van der Flier WM; Tijms BM
    Alzheimers Res Ther; 2017 Sep; 9(1):73. PubMed ID: 28899429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Alzheimer's Disease in Amnestic Mild Cognitive Impairment Subtypes: Stratification Based on Imaging Biomarkers.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Alzheimers Dis; 2016 Apr; 52(4):1385-401. PubMed ID: 27079727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests.
    Bahar-Fuchs A; Villemagne V; Ong K; Chetélat G; Lamb F; Reininger CB; Woodward M; Rowe CC
    J Alzheimers Dis; 2013; 33(2):451-62. PubMed ID: 23011220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.